Synaptogenix Inc (SNPX)

[SF Wolf]

Be sure to log in this morning and listen live to Dr. Alkon and Dr. Wilke's presentation:

Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference

News provided by
Neurotrope, Inc.
Mar 16, 2017, 08:30 ET
Share this article


NEW YORK, March 16, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease, today announced that it is scheduled to present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 10:20 a.m. Eastern Time at the Westin New York Grand Central Hotel in New York, New York. 

Neurotrope's lead compound, bryostatin-1, has demonstrated, in extensive pre-clinical studies and early clinical observations, a unique potential for multi-modal efficacy to restore degenerated synaptic networks, prevent neuronal death, and reverse cognitive deficits, while also potentially preventing the pathologic hallmarks of Alzheimer's dementia, amyloid plaques and neurofibrillary tangles. 

Susanne Wilke, PhD, Chief Executive Officer of Neurotrope BioScience and Dr. Daniel Alkon, President and Chief Scientific Officer, will be presenting at the conference.

A simultaneous live audio webcast is also available at:              https://www.veracast.com/webcasts/opco/healthcare2017/79104510713.cfm ;

A webcast replay will be available afterwards via the Company's website at www.neurotropebioscience.com under the Investors section.

Company executives will also be available for one on one meetings with investors on March 21st and 22nd.